Gouty Arthritis Market on Track for Major Expansion by 2032, According to DelveInsight | Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem

DelveInsight's "Gouty Arthritis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Gouty Arthritis, historical and forecasted epidemiology as well as the Gouty Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gouty Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gouty Arthritis Market Forecast
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Gouty Arthritis Market Report:
• The Gouty Arthritis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In August 2024, Shanton Pharma has completed subject enrollment for its Phase IIb clinical trial of SAP-001, a promising treatment for refractory and tophaceous gout. This six-month, multi-center study is randomized, double-blind, placebo-controlled, and dose-ranging. A total of 87 patients were enrolled across 21 sites in the US to evaluate the efficacy and safety of SAP-001 at three different dosage levels.
• In February 2024, Dapansutrile (lab code: OLT1177®) is an experimental small molecule that targets and inhibits NLRP3 (nucleotide-binding and oligomerization domain [NOD] , leucine-rich repeat-, pyrin domain-containing 3), a key sensor molecule involved in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes that detect danger signals inside cells and trigger a strong inflammatory response by generating bioactive IL-1β and IL-18 through caspase-1 activation. Dapansutrile has been shown to block the formation of the NLRP3 inflammasome, preventing the production of IL-1β and IL-18. It has been well tolerated and demonstrated to improve clinical outcomes in patients experiencing Gouty Arthritis and heart failure.
• The overall occurrence of gout affects 1-4% of the general population. There is a higher susceptibility to gout in men compared to women. In Western countries, the prevalence is approximately 3-6% in men and 1-2% in women.
• Gout results in around 7 million outpatient visits in the United States each year, incurring a cost of almost USD 1 billion.
• Key Gouty Arthritis Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others
• Key Gouty Arthritis Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others
• Based on the analysis, the annual incidence of gout in the UK is 2.68 cases per 1,000 individuals.
• Gout is more common in men than women. In Western countries, it affects 3-6% of men and 1-2% of women, with prevalence in some regions potentially rising to as high as 10%.
• Recent reports on the prevalence and incidence of gout show significant variation depending on the population studied and the methods used. Prevalence ranges from less than 1% to 6.8%, while incidence falls between 0.58 and 2.89 per 1,000 person-years. Gout is more common in men than women and increases with age. Both the prevalence and incidence of gout appear to be rising worldwide.
• Gout impacts around 9.2 million individuals in the US, representing about 3.9% of the adult population. It is more prevalent in men and among older adults.
• The analysis indicates that the standardized prevalence of gout in Germany was 1.63%, affecting roughly 1.325 million individuals. The standardized incidence rate was 0.45%. The male-to-female ratio was 3.2 for prevalence and 2.7 for incidence. The average age at diagnosis is estimated to be 66 years.
• The Gouty Arthritis epidemiology based on gender analyzed that Gout is three times more prevalent in males than females
• The Gouty Arthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gouty Arthritis pipeline products will significantly revolutionize the Gouty Arthritis market dynamics.

Gouty Arthritis Overview
Gouty arthritis, commonly known as gout, is a form of inflammatory arthritis caused by the buildup of uric acid crystals in the joints. It typically affects the big toe but can also impact other joints like the ankles, knees, and fingers. Gout occurs when the body produces too much uric acid or fails to eliminate it efficiently, leading to sharp crystal deposits that cause intense pain, swelling, redness, and stiffness. Risk factors include a high-purine diet, obesity, excessive alcohol consumption, certain medications, and genetic predisposition. Treatment includes anti-inflammatory medications, lifestyle changes, and uric acid-lowering therapies.

Get a Free sample for the Gouty Arthritis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/gouty-arthritis-gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gouty Arthritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gouty Arthritis Epidemiology Segmentation:
The Gouty Arthritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Gouty Arthritis
• Prevalent Cases of Gouty Arthritis by severity
• Gender-specific Prevalence of Gouty Arthritis
• Diagnosed Cases of Episodic and Chronic Gouty Arthritis

Download the report to understand which factors are driving Gouty Arthritis epidemiology trends @ Gouty Arthritis Epidemiology Forecast
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gouty Arthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gouty Arthritis market or expected to get launched during the study period. The analysis covers Gouty Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gouty Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gouty Arthritis Therapies and Key Companies
• Dapansutrile: Olatec Therapeutics
• DYV700: Dyve Biosciences
• Genakumab for injection: Changchun GeneScience Pharma
• Rilonacept: Regeneron Pharmaceuticals
• ACZ885: Novartis
• Tigulixostat: LG Chem
• Canakinumab: Novartis
• MK0663: Organon and Co
• Bucillamine: Revive Therapeutics, Ltd.

Discover more about therapies set to grab major Gouty Arthritis market share @ Gouty Arthritis Treatment Landscape
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Gouty Arthritis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gouty Arthritis Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others
• Key Gouty Arthritis Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others
• Gouty Arthritis Therapeutic Assessment: Gouty Arthritis current marketed and Gouty Arthritis emerging therapies
• Gouty Arthritis Market Dynamics: Gouty Arthritis market drivers and Gouty Arthritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gouty Arthritis Unmet Needs, KOL's views, Analyst's views, Gouty Arthritis Market Access and Reimbursement

To know more about Gouty Arthritis companies working in the treatment market, visit @ Gouty Arthritis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gouty-arthritis-gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Gouty Arthritis Market Report Introduction
2. Executive Summary for Gouty Arthritis
3. SWOT analysis of Gouty Arthritis
4. Gouty Arthritis Patient Share (%) Overview at a Glance
5. Gouty Arthritis Market Overview at a Glance
6. Gouty Arthritis Disease Background and Overview
7. Gouty Arthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Gouty Arthritis
9. Gouty Arthritis Current Treatment and Medical Practices
10. Gouty Arthritis Unmet Needs
11. Gouty Arthritis Emerging Therapies
12. Gouty Arthritis Market Outlook
13. Country-Wise Gouty Arthritis Market Analysis (2019-2032)
14. Gouty Arthritis Market Access and Reimbursement of Therapies
15. Gouty Arthritis Market Drivers
16. Gouty Arthritis Market Barriers
17. Gouty Arthritis Appendix
18. Gouty Arthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports Offered By DelveInsight:
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insigh

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.